Vertex Pharmaceuticals Incorporated (VX1.F)
| Previous close | 403.05 |
| Open | 404.90 |
| Bid | 409.15 x 10000 |
| Ask | 409.55 x 10000 |
| Day's range | 404.90 - 407.75 |
| 52-week range | 299.75 - 420.95 |
| Volume | |
| Avg. volume | 53 |
| Market cap | 105.486B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | 28.77 |
| EPS (TTM) | 14.15 |
| Earnings date | 30 July 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 258.59 |
Business WireJennifer Schneider Elected to Vertex Board of Directors
BOSTON, May 15, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jennifer Schneider, M.D., M.S., has been elected to its Board of Directors as an independent director. Dr. Schneider has more than two decades of experience in the health care industry as a physician, scientist and health care executive. She co-founded and serves as Chief Executive Officer of Homeward Health, a company committed to rearchitecting the delivery of health and care for nearly 60 million Ame
Investor's Business DailyVertex Stock Hit All-Time High, Paused, Rising Again
A Relative Strength Rating upgrade for Vertex stock shows improving technical performance. Will it continue?
ZacksHere's Why Vertex Pharmaceuticals (VRTX) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
